Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol

A. Mooranian, R. Negrulj, N.W. Chen-Tan, H.S. Al-Sallami, Z. Fang, T.K.S. Mukkur, M.M. Mikov, S. Goločorbin-Kon, M. Fakhoury, Gerald Watts, Vance Matthews, F. Arfuso, H. Al-Salami

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

© 2014 Mooranian et al. Introduction: In previous studies, we successfully designed complex multicompartmental microcapsules as a platform for the oral targeted delivery of lipophilic drugs in type 2 diabetes (T2D). Probucol (PB) is an antihyperlipidemic and antioxidant drug with the potential to show benefits in T2D. We aimed to create a novel microencapsulated formulation of PB and to examine the shape, size, and chemical, thermal, and rheological properties of these microcapsules in vitro. Method: Microencapsulation was carried out using the Büchi-based microencapsulating system developed in our laboratory. Using the polymer, sodium alginate (SA), empty (control, SA) and loaded (test, PB-SA) microcapsules were prepared at a constant ratio (1:30). Complete characterizations of microcapsules, in terms of morphology, thermal profiles, dispersity, and spectral studies, were carried out in triplicate. Results: PB-SA microcapsules displayed uniform and homogeneous characteristics with an average diameter of 1 mm. The microcapsules exhibited pseudoplastic-thixotropic characteristics and showed no chemical interactions between the ingredients. These data were further supported by differential scanning calorimetric analysis and Fourier transform infrared spectral studies, suggesting microcapsule stability. Conclusion: The new PB-SA microcapsules have good structural properties and may be suitable for the oral delivery of PB in T2D. Further studies are required to examine the clinical efficacy and safety of PB in T2D.
Original languageEnglish
Pages (from-to)1221-1230
JournalDrug Design, Development and Therapy
Volume8
DOIs
Publication statusPublished - 2014

Fingerprint

Probucol
Drug Compounding
Hypoglycemic Agents
Capsules
Type 2 Diabetes Mellitus
Hot Temperature
Hypolipidemic Agents
Fourier Analysis
Pharmaceutical Preparations
Polymers
Antioxidants
alginic acid
Safety

Cite this

Mooranian, A., Negrulj, R., Chen-Tan, N. W., Al-Sallami, H. S., Fang, Z., Mukkur, T. K. S., ... Al-Salami, H. (2014). Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. Drug Design, Development and Therapy, 8, 1221-1230. https://doi.org/10.2147/DDDT.S67349
Mooranian, A. ; Negrulj, R. ; Chen-Tan, N.W. ; Al-Sallami, H.S. ; Fang, Z. ; Mukkur, T.K.S. ; Mikov, M.M. ; Goločorbin-Kon, S. ; Fakhoury, M. ; Watts, Gerald ; Matthews, Vance ; Arfuso, F. ; Al-Salami, H. / Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. In: Drug Design, Development and Therapy. 2014 ; Vol. 8. pp. 1221-1230.
@article{4d52aa20ca5a491db9e2cc0f0375a0bf,
title = "Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol",
abstract = "{\circledC} 2014 Mooranian et al. Introduction: In previous studies, we successfully designed complex multicompartmental microcapsules as a platform for the oral targeted delivery of lipophilic drugs in type 2 diabetes (T2D). Probucol (PB) is an antihyperlipidemic and antioxidant drug with the potential to show benefits in T2D. We aimed to create a novel microencapsulated formulation of PB and to examine the shape, size, and chemical, thermal, and rheological properties of these microcapsules in vitro. Method: Microencapsulation was carried out using the B{\"u}chi-based microencapsulating system developed in our laboratory. Using the polymer, sodium alginate (SA), empty (control, SA) and loaded (test, PB-SA) microcapsules were prepared at a constant ratio (1:30). Complete characterizations of microcapsules, in terms of morphology, thermal profiles, dispersity, and spectral studies, were carried out in triplicate. Results: PB-SA microcapsules displayed uniform and homogeneous characteristics with an average diameter of 1 mm. The microcapsules exhibited pseudoplastic-thixotropic characteristics and showed no chemical interactions between the ingredients. These data were further supported by differential scanning calorimetric analysis and Fourier transform infrared spectral studies, suggesting microcapsule stability. Conclusion: The new PB-SA microcapsules have good structural properties and may be suitable for the oral delivery of PB in T2D. Further studies are required to examine the clinical efficacy and safety of PB in T2D.",
author = "A. Mooranian and R. Negrulj and N.W. Chen-Tan and H.S. Al-Sallami and Z. Fang and T.K.S. Mukkur and M.M. Mikov and S. Goločorbin-Kon and M. Fakhoury and Gerald Watts and Vance Matthews and F. Arfuso and H. Al-Salami",
year = "2014",
doi = "10.2147/DDDT.S67349",
language = "English",
volume = "8",
pages = "1221--1230",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

Mooranian, A, Negrulj, R, Chen-Tan, NW, Al-Sallami, HS, Fang, Z, Mukkur, TKS, Mikov, MM, Goločorbin-Kon, S, Fakhoury, M, Watts, G, Matthews, V, Arfuso, F & Al-Salami, H 2014, 'Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol' Drug Design, Development and Therapy, vol. 8, pp. 1221-1230. https://doi.org/10.2147/DDDT.S67349

Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. / Mooranian, A.; Negrulj, R.; Chen-Tan, N.W.; Al-Sallami, H.S.; Fang, Z.; Mukkur, T.K.S.; Mikov, M.M.; Goločorbin-Kon, S.; Fakhoury, M.; Watts, Gerald; Matthews, Vance; Arfuso, F.; Al-Salami, H.

In: Drug Design, Development and Therapy, Vol. 8, 2014, p. 1221-1230.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol

AU - Mooranian, A.

AU - Negrulj, R.

AU - Chen-Tan, N.W.

AU - Al-Sallami, H.S.

AU - Fang, Z.

AU - Mukkur, T.K.S.

AU - Mikov, M.M.

AU - Goločorbin-Kon, S.

AU - Fakhoury, M.

AU - Watts, Gerald

AU - Matthews, Vance

AU - Arfuso, F.

AU - Al-Salami, H.

PY - 2014

Y1 - 2014

N2 - © 2014 Mooranian et al. Introduction: In previous studies, we successfully designed complex multicompartmental microcapsules as a platform for the oral targeted delivery of lipophilic drugs in type 2 diabetes (T2D). Probucol (PB) is an antihyperlipidemic and antioxidant drug with the potential to show benefits in T2D. We aimed to create a novel microencapsulated formulation of PB and to examine the shape, size, and chemical, thermal, and rheological properties of these microcapsules in vitro. Method: Microencapsulation was carried out using the Büchi-based microencapsulating system developed in our laboratory. Using the polymer, sodium alginate (SA), empty (control, SA) and loaded (test, PB-SA) microcapsules were prepared at a constant ratio (1:30). Complete characterizations of microcapsules, in terms of morphology, thermal profiles, dispersity, and spectral studies, were carried out in triplicate. Results: PB-SA microcapsules displayed uniform and homogeneous characteristics with an average diameter of 1 mm. The microcapsules exhibited pseudoplastic-thixotropic characteristics and showed no chemical interactions between the ingredients. These data were further supported by differential scanning calorimetric analysis and Fourier transform infrared spectral studies, suggesting microcapsule stability. Conclusion: The new PB-SA microcapsules have good structural properties and may be suitable for the oral delivery of PB in T2D. Further studies are required to examine the clinical efficacy and safety of PB in T2D.

AB - © 2014 Mooranian et al. Introduction: In previous studies, we successfully designed complex multicompartmental microcapsules as a platform for the oral targeted delivery of lipophilic drugs in type 2 diabetes (T2D). Probucol (PB) is an antihyperlipidemic and antioxidant drug with the potential to show benefits in T2D. We aimed to create a novel microencapsulated formulation of PB and to examine the shape, size, and chemical, thermal, and rheological properties of these microcapsules in vitro. Method: Microencapsulation was carried out using the Büchi-based microencapsulating system developed in our laboratory. Using the polymer, sodium alginate (SA), empty (control, SA) and loaded (test, PB-SA) microcapsules were prepared at a constant ratio (1:30). Complete characterizations of microcapsules, in terms of morphology, thermal profiles, dispersity, and spectral studies, were carried out in triplicate. Results: PB-SA microcapsules displayed uniform and homogeneous characteristics with an average diameter of 1 mm. The microcapsules exhibited pseudoplastic-thixotropic characteristics and showed no chemical interactions between the ingredients. These data were further supported by differential scanning calorimetric analysis and Fourier transform infrared spectral studies, suggesting microcapsule stability. Conclusion: The new PB-SA microcapsules have good structural properties and may be suitable for the oral delivery of PB in T2D. Further studies are required to examine the clinical efficacy and safety of PB in T2D.

U2 - 10.2147/DDDT.S67349

DO - 10.2147/DDDT.S67349

M3 - Article

VL - 8

SP - 1221

EP - 1230

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -